HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

CETP inhibitor obicetrapib slowed p-tau217 accumulation in the BROADWAY analysis

Louis Nervegna · Sep 05, 2025 · ♥ 7 reactions · 1 comments · original Facebook post
PCSK9, ezetimibe & newer drugsBrain health & dementiaLDL, ApoB & lipid panel
AI summary & key facts

Louis notes that HDL-raising drugs failed for heart disease but may have value for Alzheimer's. In a secondary analysis of the BROADWAY trial presented at AAIC, the CETP inhibitor obicetrapib slowed rise of the Alzheimer's biomarker p-tau217 versus placebo.

Drugs to raise HDL failed miserably in clinical trials for heart disease.

But they may have value in treating Alzheimer’s.

Quoted:

“This was from a prespecified secondary analysis of data from a cardiovascular-focused trial of obicetrapib called BROADWAY, primary results from which were reported in May. The drug works by blocking conversion of high-density lipoprotein (HDL) cholesterol into the low-density form (LDL). CETP inhibitors were all the rage a few years ago as a novel approach to cholesterol management, but poor results with the first wave of candidates didn't meet expectations.”

“But research on the interplay of cholesterol metabolism and Alzheimer's disease led the company to keep an eye on obicetrapib's effects on Alzheimer's disease biomarkers. "Lipid dysregulation is very important for Alzheimer's disease, it's an important risk factor, especially with APOE4," he told attendees. "Obicetrapib actually has the ability to significantly change p-tau progression over time as compared with placebo."

“The investigators' belief, Scheltens said, is that these effects are not a consequence of diminished HDL-LDL conversion, but rather some type of direct action on Alzheimer's pathology.”

#hdlHD #alzheimersHD #dementiaHD #obicetrapibHD #cetpinhibitorHD #broadwayHD #ptau217HD #apoe4HD

Research cited

A heart drug slowed the accumulation of phosphorylated tau protein-217 (p-Tau 217) in those with cardiovascular disease in a new trial. Those familiar with BrainScan will recognize p-Tau 217 as one of the biomarkers tested to detect cognitive decline. While the drug (obicetrapib) targets cholesterol metabolism, much of the benefit may simply come from improved cardiovascular health. Link to medpagetoday.com (medpagetoday.com)

No photo description available.
← newer: AHA limits added sugar to 36 g/day for men and 25 g/day for older: Omega-3 and omega-6 fatty acids associated with less daytime →